Key facts
- It has raised $40.8M; the latest was Later Stage VC ($14.1M) in Feb 2025.
- Notable investors include European Innovation Council, Omnes Capital, Wille Finance, Indaco Venture Partners, Enea Tech e Biomedical — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Newronika
- ·The full record, as it builds
Funding rounds
No funding rounds for Newronika are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Newronika
Developer of a neuro-modulation device designed to restore brain and body functioning. The company's therapeutic device uses the retro-activity system to record brain activity and modulate neuro-stimulation to collect, analyze, and interpret bio-signals, enabling patients to receive the right stimulation at the right moment to perform normal daily activities and improve their quality of life.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2008
- Employees
- 23
- Website
- newronika.com/
- Ownership
- Privately Held (backing)
Newronika doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Newronika shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Newronika in its N-PORT filings yet. We sweep new filings monthly.